Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

133.10USD
10:40pm IST
Change (% chg)

$-2.12 (-1.57%)
Prev Close
$135.22
Open
$133.34
Day's High
$134.22
Day's Low
$133.02
Volume
619,053
Avg. Vol
1,876,571
52-wk High
$137.07
52-wk Low
$109.32

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $362,930.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.48

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.11
EPS (TTM): -- -- --
ROI: -- 14.34 15.45
ROE: -- 15.64 13.75

UPDATE 2-Pfizer files suit against J&J over Remicade contracts

Sept 20 Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

10:02pm IST

Pfizer sues Johnson & Johnson over Remicade biosimilar

Sept 20 Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying that the drugmaker's anticompetitive contracts with health insurers prevented biosimilar competition to its blockbuster rheumatoid arthritis drug, Remicade.

7:13pm IST

BRIEF-‍Pfizer files lawsuit against Johnson & Johnson​

* ‍Pfizer says filed suit in U.S. District Court for Eastern District of Pennsylvania against Johnson & Johnson​

7:09pm IST

European panel backs Janssen's psoriasis drug

A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen's drug, guselkumab, for the treatment of plaque psoriasis in adults.

15 Sep 2017

UPDATE 1-European panel backs Janssen's psoriasis drug

Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen's drug, guselkumab, for the treatment of plaque psoriasis in adults.

15 Sep 2017

European panel recommends approval of J&J's psoriasis drug

Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen's drug, guselkumab, for the treatment of plaque psoriasis in adults.

15 Sep 2017

BRIEF-Integra Lifesciences to sell neurosurgery assets to Natus Medical

* Integra Lifesciences announces definitive agreement to sell certain neurosurgery assets to Natus Medical Incorporated

11 Sep 2017

J&J unit ends hepatitis C drug development in crowded market

Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.

11 Sep 2017

J&J unit ends hepatitis C drug development in crowded market

Sept 11 Janssen Sciences Ireland UC, a unit of Johnson & Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.

11 Sep 2017

Bayer, J&J in frame for bigger anti-clotting market opportunity

FRANKFURT Bayer and Johnson & Johnson's blockbuster clot prevention drug Xarelto was shown to cut the risk of potentially deadly strokes and heart attacks in patients with severe atherosclerosis by 24 percent, raising the prospects of billions more in sales.

27 Aug 2017

Earnings vs. Estimates